After Mizuho Securities and Stifel Nicolaus gave Revance Therapeutics (NASDAQ: RVNC) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Serge Belanger maintained a Buy rating on Revance Therapeutics today and set a price target of $32.00. The company’s shares closed last Monday at $15.81.
According to TipRanks.com, Belanger is a 1-star analyst with an average return of -1.3% and a 43.0% success rate. Belanger covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals, Collegium Pharmaceutical, and Zynerba Pharmaceuticals.
Revance Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.33, which is an 113.0% upside from current levels. In a report issued on October 30, Wells Fargo also upgraded the stock to Buy with a $20.00 price target.
See today’s analyst top recommended stocks >>
Based on Revance Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $37.39 million. In comparison, last year the company had a GAAP net loss of $32.83 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.